Brief: Northwest Biotherapeutics plans to use proceeds of offering for initiating Phase II clinical trials
23/08/2016 14:30
Aug 23 (Reuters) - Northwest Biotherapeutics Inc NWBO.O
* Entered into agreements with certain holders of offered
warrants - SEC Filing
* Pursuant to agreement holders are exercising all of their
offered warrants to purchase 3.7 million shares of common stock,
* In consideration, Co agreed to reduce exercise price of
offered warrants to $0.35/share for gross proceeds of about $1.3
million
* Plans to use proceeds of offering for costs related to
preparing for and initiating Phase II clinical trials
Source text: [http://bit.ly/2c2JAXw]
Further company coverage: NWBO.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB